PMN

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Retrieved on: 
水曜日, 5月 22, 2024
Breakthrough therapy, ODD, BofA Securities, BIIB, European Renal Association, Patient, Manufacturing execution system, Covington & Burling, Kidney, Food, IgA nephropathy, NK, FDA, AMR, Congress, PMN, Biomarker, Acquisition, BTD, Cell, B cell, Abstract, ERA, Immunoglobulin A, Vaccine

Biogen seeks to retain expertise and talent from HI-Bio and establish a San Francisco Bay Area team focused on expanding our efforts in immune-mediated diseases.

Key Points: 
  • Biogen seeks to retain expertise and talent from HI-Bio and establish a San Francisco Bay Area team focused on expanding our efforts in immune-mediated diseases.
  • Under the terms of the agreement, Biogen will make an upfront payment to HI-Bio of $1.15 billion.
  • Biogen expects to finance the acquisition with cash and may also draw on its revolving credit agreement.
  • Goldman Sachs & Co. LLC and BofA Securities, Inc. acted as financial advisors to HI-Bio and Goodwin Procter LLP acted as its legal advisor.

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

Retrieved on: 
火曜日, 5月 14, 2024
PROMIS, Patient, CSF, Pharmacokinetics, SOD1, Toxicity, Immunoglobulin G, Synucleinopathy, Trial of the century, Safety, ALS, Biochemistry, Blood, PMN, Bioorganic chemistry, Vaccination, BioRxiv, Cerebrospinal fluid, Journal, Multiple system atrophy, Research, Therapy, MSA, Biotechnology, Epitope, Neuroscience, Pharmaceutical industry

In January 2024, ProMIS announced the selection of a lead vaccine candidate, PMN400, against multiple synucleinopathies including MSA, Parkinson’s disease and Lewy Body Dementia.

Key Points: 
  • In January 2024, ProMIS announced the selection of a lead vaccine candidate, PMN400, against multiple synucleinopathies including MSA, Parkinson’s disease and Lewy Body Dementia.
  • In January 2024, ProMIS announced the appointment of Neil Warma as the interim Chief Executive Officer.
  • General and administrative expenses modestly increased to $1.6 million for the quarter ended March 31, 2024, compared to $1.4 million for the same period in 2023.
  • Net loss was $3.6 million for the quarter ended March 31, 2024, compared to a net loss of $5.0 million for the same period in 2023.

GMG Provides Commercialisation Update on Energy Savings Coating THERMAL-XR(R)

Retrieved on: 
月曜日, 4月 22, 2024
ASHRAE, PMN, Data center, Sale, EPA, AAON, Graphene, Disruptive innovation, Natural gas, Conference, Research, Plant, Air conditioning, Corrosion, GMG, HVACR, HVAC, Customer engagement, The Company, Online shopping

Vancouver, BC, Apr 23, 2024 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to provide a business update on the commercialisation progress of THERMAL-XR(R) powered by GMG Graphene.

Key Points: 
  • Vancouver, BC, Apr 23, 2024 - (ACN Newswire) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to provide a business update on the commercialisation progress of THERMAL-XR(R) powered by GMG Graphene.
  • GMG and GMG's THERMAL-XR(R) powered by GMG Graphene coating was awarded as Most Disruptive Technology Award and Best Chance for Market Success Award at the Data Center World Conference in Washington DC, USA on the 18th April 2024.
  • GMG's THERMAL-XR(R) can provide high Corrosion Protection whilst potentially providing energy savings for their HVAC equipment.
  • GMG's Managing Director and CEO, Craig Nicol, commented: "The progress GMG is making with THERMAL-XR(R) is exciting.

Regulatory Clearance for Leo Cancer Care's Upright Technology for Radiation Therapy

Retrieved on: 
木曜日, 5月 9, 2024
FDA, PMN, Cancer, Radiation, Food, Research, Patient, Movement, Pharmaceutical industry

MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients. This 510(K) clearance means that the Eve System can now be used to offer 'a more human' method of treating cancer patients.

Key Points: 
  • 510k regulatory clearance for Leo Cancer Care's unique patient positioning system, Eve®, paves the way for a new approach to patient treatment
    MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients.
  • The patient positioning system enables cancer patients to receive radiation treatment seated in an upright position.
  • The FDA regulatory clearance for Leo Cancer Care's upright technology is a truly significant step in the company's evolution, and also in the way radiation therapy can now be delivered to patients.
  • Towe said that with one device cleared, Leo Cancer Care has a comprehensive development pipeline to deliver further solutions within the upright technology paradigm.

Regulatory Clearance for Leo Cancer Care's Upright Technology for Radiation Therapy

Retrieved on: 
木曜日, 5月 9, 2024
FDA, PMN, Cancer, Radiation, Food, Research, Patient, Movement, Pharmaceutical industry

MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients. This 510(K) clearance means that the Eve System can now be used to offer 'a more human' method of treating cancer patients.

Key Points: 
  • 510k regulatory clearance for Leo Cancer Care's unique patient positioning system, Eve®, paves the way for a new approach to patient treatment
    MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients.
  • The patient positioning system enables cancer patients to receive radiation treatment seated in an upright position.
  • The FDA regulatory clearance for Leo Cancer Care's upright technology is a truly significant step in the company's evolution, and also in the way radiation therapy can now be delivered to patients.
  • Towe said that with one device cleared, Leo Cancer Care has a comprehensive development pipeline to deliver further solutions within the upright technology paradigm.

TMC & SGS Produce World-First Nickel Sulfate from Deep-Seafloor Polymetallic Nodules

Retrieved on: 
火曜日, 4月 23, 2024
Copper, PMN, Glacier Media, TMC, Metal, Partnership, Collection, House, Metallurgy, Manganese, Cobalt, Engineering, Extractive metallurgy, Steel, Representative, SGS, The Metals Company, Municipal solid waste, Nickel

The sulfate was generated during bench-scale testing of its hydrometallurgical flowsheet design in partnership with SGS Canada Inc., at their Lakefield, Ontario facility.

Key Points: 
  • The sulfate was generated during bench-scale testing of its hydrometallurgical flowsheet design in partnership with SGS Canada Inc., at their Lakefield, Ontario facility.
  • Undertaken on samples of nickel-cobalt-copper matte produced by TMC in 2021, the Extractive Metallurgy team at SGS tested TMC’s efficient flowsheet to process high-grade nickel matte directly to nickel sulfate without making nickel metal, while producing fertilizer byproducts instead of solid waste or tailings.
  • Following the successful nickel sulfate production, SGS continues testing to produce what TMC believes will be the world’s first cobalt sulfate from polymetallic nodules.
  • This work was executed in close collaboration with SGS and other industry leaders to demonstrate the ability to refine nodules to high value products.

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Retrieved on: 
火曜日, 4月 9, 2024
Toxicity, PMN, MSA, Bioorganic chemistry, ALS, Multiple system atrophy, Zebrafish, SOD1, Neuroscience, Journal, Brain cell, TAR, Protein, Biochemistry, PROMIS, Antibody, Therapy, Vaccine

ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.

Key Points: 
  • ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.
  • ALS is a fatal neurodegenerative disease of motor neurons.
  • “Publication of these data underscores the connection of misfolded proteins and ALS and supports targeting our TDP-43-specific epitope with PMN267 as a potential therapeutic approach,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
  • “PMN267 is advancing through preclinical development and is showing promise as a potential treatment for ALS.

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April 

Retrieved on: 
木曜日, 4月 4, 2024
Therapy, PMN, Communications satellite

ET.

Key Points: 
  • ET.
  • Neil Warma, Chief Executive Officer, will present a corporate overview on Thursday, April 11, 2024 at 2:15 p.m.
  • Neil Warma, Chief Executive Officer, will present a corporate overview on Wednesday, April 17, 2024 at 10:30 a.m.
  • A live webcast of the presentations may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com , and will be available for at least 30 days following the event.

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
月曜日, 4月 1, 2024
Research, PMN, FTLD, Biotechnology, MSA, ALS, Multiple system atrophy, CSF, Patient, Neuroscience, Epitope, Immunoglobulin G, RACK1, Cerebrospinal fluid, Activated, Synucleinopathy, Clinical trial, PROMIS, Antibody, Vaccination, Safety, Pharmacokinetics, Interim, Therapy, Blood, SAD, Frontotemporal lobar degeneration, Pharmaceutical industry

This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.

Key Points: 
  • This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.
  • ProMIS dosed the first participants in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for AD in November 2023 (Study NCT06105528 ).
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Cash and cash equivalents were $12.6 million as of December 31, 2023, compared to $5.9 million as of December 31, 2022.

Leading Innovator Alef Redefines Enterprise Mobile Networking with its Cutting-Edge Solution

Retrieved on: 
月曜日, 3月 11, 2024
Automation, PMN, Intelligence, AI, Software, API, Patent, Aleph, TechCrunch, Mobile phone

NEW YORK, March 11, 2024 /PRNewswire/ -- Alef, a leading innovator in the realm of enterprise-ready mobile connectivity solutions, is poised to revolutionize the mobile infrastructure landscape with its state-of-the-art software-defined AI-powered platform. As the demand for intelligent, high-performance, cost-efficient, and easily scalable networks continues to be a top priority for CIOs, Alef emerges as a unique solution provider, enabling the AI mobile infrastructure discussed in the recent TechCrunch article, "Winning wireless with American strengths."

Key Points: 
  • NEW YORK, March 11, 2024 /PRNewswire/ -- Alef , a leading innovator in the realm of enterprise-ready mobile connectivity solutions, is poised to revolutionize the mobile infrastructure landscape with its state-of-the-art software-defined AI-powered platform.
  • "By combining AI and edge computing, Alef is shaping the future of mobile networks," added Mulica.
  • "Our solutions empower mobile network operators to stay ahead of the curve and deliver the next generation of wireless services to their enterprise customers."
  • As the mobile industry evolves, Alef remains at the forefront of innovation, providing the technologies and expertise needed to build the AI-powered mobile infrastructure of tomorrow.